Precision BioSciences Announces Pricing of $125 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
PRECISION BIOSCIENCES INC (DTIL) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Precision BioSciences Announces Pricing of $125 Million Underwritten Offering of Common Stock and Pre-Funded Warrants DURHAM, N.C.—November 5, 2026 – Precision BioSciences, Inc. (Nasdaq: DTIL) (“Precision”), a clinical stage gene editing company utilizing its novel p
How this was made
The 30-second read
Why it matters
The raise provides cash for R&D on PBGENE‑HBV and PBGENE‑DMD but introduces dilution risk, likely pressuring the share price in the short term.
Market read
Primary disclosure of a sizable capital raise; immediate dilution risk makes the news highly relevant for traders.
What to watch
Potential strategic investors participating may signal confidence in the pipeline, mitigating dilution concerns.
Background
Precision BioSciences (NASDAQ:DTIL) is a clinical‑stage gene‑editing company using its ARCUS platform. The company announced a $125 million equity raise via a public offering of common stock and pre‑funded warrants.
Ticker impact
Precision BioSciences disclosed pricing of a $125 million underwritten offering of common stock and pre‑funded warrants.
likely downside as market prices in dilution from the $125 M raise
New primary disclosure of a sizable equity raise; dilution risk is immediate and material.
Market effects
May weigh on other gene‑editing and biotech stocks due to perceived financing pressure.
Limited to US biotech sector; no broader regional effect.
Minimal global impact beyond biotech investors.
Counterpoint
If the capital is deployed successfully into pipeline candidates, the long‑term upside could outweigh short‑term dilution.
Key entities
- companyPrecision BioSciences
Clinical‑stage gene‑editing firm issuing new equity.
- financial_institutionTD Cowen
Joint book‑running manager for the offering.
- financial_institutionGuggenheim Securities
Joint book‑running manager for the offering.
